Nektar TherapeuticsNKTRNASDAQ
Loading
ROE: Returns DecliningContracting
Percentile Rank29
Studio
Year-over-Year Change

Return on equity

Latest
-182.65%
↓ 68% vs avg
Percentile
P29
Within normal range
Streak
2 yr
Consecutive growthContracting
Average
-108.40%
Historical baseline
PeriodValueYoY Change
2025-182.65%+6.7%
2024-195.86%+7.1%
2023-210.75%-109.9%
2022-100.43%-30.3%
2021-77.09%-86.9%
2020-41.26%-31.6%
2019-31.36%-179.0%
201839.67%+136.0%
2017-110.09%+36.8%
2016-174.21%-